The National Institutes of Health’s National Cancer Institute (NCI) has awarded a grant for up to $3 million to NuvOx Pharma to initiate a Phase II clinical trial for the investigational drug, DDFPe, in the brain cancer, glioblastoma multiforme (GBM).
top of page
Search
Recent Posts
See AllTucson, AZ, September 6th, 2024 – NuvOx Pharma LLC, a wholly owned subsidiary of NuvOx Therapeutics Inc. (together, “NuvOx”) announced...
Tucson, AZ, June 30th, 2024 – NuvOx Pharma LLC (“NuvOx”) announced that it has received authorization from Health Canada for its EXTEND:...
Tucson, AZ, January 2, 2024 - NuvOx Pharma has been issued US Patent No. 11,857,627, entitled “Fractionated Radiotherapy and...
bottom of page
Comments